Statin therapy and increased coronary heart disease risk in primary prevention of people with enhanced low-grade inflammation

Turkiye Klinikleri Cardiovascular Sciences

Volumn 26, Issue 3, 2014, Pages 118-127

  Onat, Altan ^a   Aydin, Mesut ^b   Köroʇlu, Bayram ^c   Can, Günay ^a   Kaya, Hasan ^b   Ademoʇlu, Evin ^d  

^a ISTANBUL UNIVERSITY   (Turkey)

^b DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c Training and Research Hospital   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Autoimmunity; Coronary disease; Hydroxymethylglutaryl CoA reductase inhibitors; Lipoprotein(a); Primary prevention

Indexed keywords

APOLIPOPROTEIN B; CREATININE; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG USE; ENHANCED LOW GRADE INFLAMMATION; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; FRAMINGHAM RISK SCORE; GROUPS BY AGE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIMARY PREVENTION; PROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING;

EID: 84919381173     PISSN: 13067656     EISSN: 21469032     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78.
2. Armitage J. The safety of statins in clinical practice. Lancet 2007;370(9601):1781-90.
3. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterollowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371(9607):117-25.
4. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-207.
5. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32(10):1924-9.
6. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, De Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375(9716):735-42.
7. Onat A, Kömürcü-Bayrak E, Can G, Küçükdurmaz Z, Hergenç G, Erginel-Unaltuna N. Apolipoprotein A-I positively associated with diabetes in women independently of apolipoprotein E genotype and apolipoprotein B levels. Nutrition 2010;26(10):975-80.
8. Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007;191(1):182-90.
9. Onat A, Can G, Murat S, Ciçek G, Örnek E, Yüksel H. Aggregation of lipoprotein (a) to apolipoprotein A-I underlying HDL dysfunction as a major coronary risk factor. Anadolu Kardiyol Derg 2013;13(6):543-51.
10. Onat A, Can G, Ornek E, Ayhan E, Erginel-Ünaltuna N, Murat SN. High serum apolipoprotein E determines hypertriglyceridemic dyslipidemias, coronary disease and apoA-I dysfunctionality. Lipids 2013;48(1):51-61.
11. Onat A, Sari I, Hergenç G, Yazici M, Uyarel H, Can G, et al. Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study. Metabolism 2007;56(3):348-56.
12. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels-a prospective and cross-sectional evaluation. Atherosclerosis 2002;165(2):285-92.
13. Onat A, Can G, Yüksel H, Ayhan E, Dogan Y, Hergenç G. An algorithm to predict risk of type 2 diabetes in Turkish adults: contribution of C-reactive protein. J Endocrinol Invest 2011;34(8):580-6.
14. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001;156(1):1-10.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
16. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109(3):433-8.
17. Rose G, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods. 2nd ed. Geneva: WHO; 1982. p. 124-7.
18. Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 2012;60(14):1231-8.
19. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172(2):144-52.
20. Waters DD, Ho JE, Boekholdt SM, De Micco DA, Kastelein JJ, Messig M, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013;61(2):148-52.
21. Taylor AJ, Villines TC, Stanek EJ. Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe. Eur Heart J 2012;33(23):2939-45.
22. Myasoedova E, Crowson CS, Kremers HM, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010;69(7):1310-4.
23. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012;307(1):56-65.
24. Baudhuin LM, Hartman SJ, O'Brien JF, Meissner I, Galen RS, Ward JN, et al. Electrophoretic measurement of lipoprotein (a) cholesterol in plasma with and without ultracentrifugation: comparison with an immunoturbidimetric lipoprotein (a) method. Clin Biochem 2004;37(6):481-8.
25. Wang JJ, Gong JB, Li HQ, Niu DM, Han AZ, Wu J, et al. Lipoprotein (a) complexes with beta2-glycoprotein I in patients with coronary artery disease. J Atheroscler Thromb 2012;19(1):81-9.
26. Gonbert S, Malinsky S, Sposito AC, Laouenan H, Doucet C, Chapman MJ, et al. Atorvastatin lowers lipoprotein (a) but not apolipoprotein (a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002;164(2):305-11.
27. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp (a) levels. Circulation 1989;80(5):1313-9.
28. Kolski B, Tsimikas S. Emerging therapeutic agents to lower lipoprotein (a) levels. Curr Opin Lipidol 2012;23(6):560-8.
29. Choi SH, Chae A, Miller E, Messig M, Ntanios F, De Maria AN, et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol 2008;52(1):24-32.
30. Rodenburg J, Vissers MN, Wiegman A, Miller ER, Ridker PM, Witztum JL, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol 2006;47(9):1803-10.
31. Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 2013;61(25):2495-502.
32. Ballantyne CM, Herd JA, Stein EA, Ferlic LL, Dunn JK, Gotto AM Jr, et al. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 2000;36(5):1572-8.
33. Baptista R, Rebelo M, Decq-Mota J, Dias P, Monteiro P, Providência LA, et al. Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy. Lipids Health Dis 2011 Mar. 30; 10:48. doi: 10.1186/1476-511X-10-48.
34. Larsen S, Stride N, Hey-Mogensen M, Hansen CN, Bang LE, Bundgaard H, et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol 2013;61(1):44-53.
35. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302(4):412-23.
36. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al.; European Atherosclerosis Society Consensus Panel. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31(23):2844-53.
37. Kotani K, Yamada S, Yamada T, Taniguchi N, Sakurabayashi I. The relationship between oxidized lipoprotein (a) and carotid atherosclerosis in asymptomatic subjects: a comparison with native lipoprotein (a). Lipids Health Dis 2011 Oct. 4; 10:174. doi: 10.1186/1476-511X-10-174.